Eric Coldwell
Stock Analyst at Baird
(3.50)
# 739
Out of 5,182 analysts
168
Total ratings
57.63%
Success rate
1.69%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings | Maintains: Outperform | $565 → $477 | $417.54 | +14.24% | 20 | Apr 24, 2026 | |
| DGX Quest Diagnostics | Maintains: Neutral | $224 → $229 | $192.67 | +18.86% | 12 | Apr 22, 2026 | |
| FTRE Fortrea Holdings | Maintains: Outperform | $19 → $16 | $12.18 | +31.36% | 10 | Feb 27, 2026 | |
| LH Labcorp Holdings | Maintains: Outperform | $313 → $326 | $255.84 | +27.42% | 15 | Feb 18, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $44.75 | +7.26% | 1 | Jan 12, 2026 | |
| MCK McKesson | Maintains: Outperform | $873 → $927 | $814.02 | +13.88% | 18 | Nov 6, 2025 | |
| CRL Charles River Laboratories International | Upgrades: Outperform | $178 → $199 | $165.78 | +20.04% | 15 | Nov 6, 2025 | |
| IQV IQVIA Holdings | Upgrades: Outperform | $224 → $258 | $157.77 | +63.53% | 19 | Oct 29, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $112.85 | +98.49% | 22 | Sep 2, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $195.24 | +3.97% | 13 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $13.17 | +21.49% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $59.95 | -24.94% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $82.09 | -19.60% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $0.89 | +5,082.51% | 4 | Nov 10, 2017 |
Medpace Holdings
Apr 24, 2026
Maintains: Outperform
Price Target: $565 → $477
Current: $417.54
Upside: +14.24%
Quest Diagnostics
Apr 22, 2026
Maintains: Neutral
Price Target: $224 → $229
Current: $192.67
Upside: +18.86%
Fortrea Holdings
Feb 27, 2026
Maintains: Outperform
Price Target: $19 → $16
Current: $12.18
Upside: +31.36%
Labcorp Holdings
Feb 18, 2026
Maintains: Outperform
Price Target: $313 → $326
Current: $255.84
Upside: +27.42%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $44.75
Upside: +7.26%
McKesson
Nov 6, 2025
Maintains: Outperform
Price Target: $873 → $927
Current: $814.02
Upside: +13.88%
Charles River Laboratories International
Nov 6, 2025
Upgrades: Outperform
Price Target: $178 → $199
Current: $165.78
Upside: +20.04%
IQVIA Holdings
Oct 29, 2025
Upgrades: Outperform
Price Target: $224 → $258
Current: $157.77
Upside: +63.53%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $112.85
Upside: +98.49%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $195.24
Upside: +3.97%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $13.17
Upside: +21.49%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $59.95
Upside: -24.94%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $82.09
Upside: -19.60%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $0.89
Upside: +5,082.51%